Copeptin in heart failure: Review and meta-analysis

Yao, Zhong; Wu, Rui; Yan, Lulu; Lin, Man; Liu, Xingling; You, Tianhui

doi:10.1016/j.cca.2017.10.001

Cited by 41 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…sST2, a member of the interleukin (IL)-1 receptor family and defined as a ligand for IL-33, is considered a cardiovascular stress protein, associated with fibrosis, cardiac and vascular remodelling and inflammation 72. Initial evidence also indicates that other novel biomarkers, such as CT-proAVP20 73 74 and MR-proADM,75 both biomarkers of neurohormonal activation, also have prognostic value in HF.…”

Section: Discussionmentioning

confidence: 99%

Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis

2018

View full text Add to dashboard Cite

BackgroundBiomarkers are important in the diagnosis, risk stratification and management of patients with heart failure (HF). The established biomarkers of myocardial stretch, brain natriuretic peptide (BNP) and amino (N) portion of BNP (NT-proBNP) have been extensively studied, and early analyses have demonstrated response to exercise training. Several other biomarkers have been identified over the last decade and may provide valuable and complementary information which may guide treatment strategies, including exercise therapy.MethodsA systematic search of PubMed, EMBASE and Cochrane Trials Register to 31 October 2017 was conducted for exercise-based rehabilitation trials in HF. Randomised and controlled trials that reported biomarkers, BNP, NT-proBNP, soluble ST2, galectin-3, mid-regional atrial natriuretic peptide, mid-regional adrenomedullin and copeptin, were included.ResultsForty-three studies were included in the systematic review, with 27 studies suitable for meta-analyses. Data pooling was only possible for NT-proBNP and BNP. Meta-analyses of conventional training studies demonstrated a statistically significant improvement in NT-proBNP (pmol/L); mean difference (MD) −32.80 (95% CI −56.19 to −9.42), p=0.006 and in BNP (pmol/L); MD −17.17 (95% CI −29.56 to −4.78), p=0.007. Pooled data of non-conventional training failed to demonstrate any statistically significant improvements.ConclusionPooled data indicated a favourable effect of conventional exercise therapy on the established biomarkers, NT-proBNP and BNP; however, this was in contrast to a number of studies that could not be pooled. Limited evidence exists as to the effect of exercise training on emerging biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis

2018

View full text Add to dashboard Cite

show abstract

“…27 A recent meta-analysis comprising 10 prospective cohort studies demonstrated that the predictive value of copeptin is comparable with NT-proBNP for all-cause mortality in HF patients. 28 However, the possible use of copeptin as a target in biomarker-guided therapy in clinical practice remains to be investigated.…”

Section: Copeptinmentioning

confidence: 99%

Cardiovascular biomarkers predict post‐discharge re‐hospitalization risk and mortality among Swedish heart failure patients

et al. 2019

View full text Add to dashboard Cite

AimThe aim of this study was to assess the predictive role of biomarkers, associated with cardiovascular stress and its neuroendocrine response as well as renal function, in relation to mortality and risk of re‐hospitalization among consecutive patients admitted because of heart failure (HF).Methods and resultsA total of 286 patients (mean age, 75 years; 29% women) hospitalized for newly diagnosed or exacerbated HF were analysed. Associations between circulating levels of mid‐regional pro‐adrenomedullin (MR‐proADM), copeptin, C‐terminal pro‐endothelin‐1, N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), cystatin C, and all‐cause mortality as well as risk of re‐hospitalization due to cardiac causes were assessed using multivariable Cox regression models. A two‐sided Bonferroni‐corrected P‐value of 0.05/5 = 0.010 was considered statistically significant. All biomarkers were related to echocardiographic measurements of cardiac dimensions and function. A total of 57 patients died (median follow‐up time, 17 months). In the multivariable‐adjusted Cox regression analyses, all biomarkers, except C‐terminal pro‐endothelin‐1, were significantly associated with increased mortality: NT‐proBNP [hazard ratio (HR) 1.85, 95% confidence interval (CI) 1.17–2.17; P = 4.0 × 10−4], MR‐proADM (HR 1.94, 95% CI 1.36–2.75; P = 2.2 × 10−4), copeptin (HR 1.70, 95% CI 1.22–2.36; P = 0.002), and cystatin C (HR 2.11, 95% CI 1.56–2.86; P = 1.0 × 10−6). A total of 90 patients were re‐hospitalized (median time to re‐hospitalization, 5 months). In multivariable Cox regression analyses, NT‐proBNP was the only biomarker that showed significant association with risk of re‐hospitalization due to cardiac causes (HR 1.43, 95% CI 1.10–1.87; P = 0.009).ConclusionsAmong patients hospitalized for HF, elevated plasma levels of NT‐proBNP, MR‐proADM, copeptin, and cystatin C are associated with higher mortality after discharge, whereas NT‐proBNP is the only biomarker that predicts the risk of re‐hospitalization due to cardiac causes.

show abstract

“…[ 7 ] Copeptin is a homologous peptide to AVP. [ 9 , 10 ] It is more stable and easier to detect in serum. [ 9 , 11 ] During CHF, the level of copeptin also increases and is positively correlated with the AVP level.…”

Section: Introductionmentioning

confidence: 99%

“…[ 9 , 10 ] It is more stable and easier to detect in serum. [ 9 , 11 ] During CHF, the level of copeptin also increases and is positively correlated with the AVP level. [ 9 , 12 ] Therefore, the serum copeptin level is becoming more and more popular for CHF prediction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction

Liu

et al. 2018

Medicine

View full text Add to dashboard Cite

This study aimed to evaluate the clinical applicability of the plasma copeptin level to assess heart failure with reduced left ventricular ejection fraction (HFrEF).One hundred thirty-one patients with HFrEF, 127 patients with heart failure with preserved left ventricular ejection fraction (HFpEF), and 119 healthy candidates were involved. The basic data and examination results of patients were collected. The heart function of the patients with HFrEF and HFpEF were graded on the basis of the criteria of New York Heart Association (NYHA) classification. The plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were tested using enzyme-linked immunosorbent assays (ELISAs).The copeptin and NT-proBNP levels were higher in the HFrEF group than in the HFpEF group. The copeptin and NT-proBNP values increased as the NYHA grade increased in the patients with HFrEF. However, for the patients with HFpEF, the copeptin levels did not change markedly as the NYHA grade increased. The copeptin levels were positively correlated with the NT-proBNP levels in the patients with HFrEF; however, there was no correlation between the copeptin and NT-proBNP values in the patients with HFpEF.Copeptin is involved in the process of progression in patients with HFrEF and the copeptin values might be useful for HFrEF prediction and assessment in the clinic.

show abstract

Copeptin in heart failure: Review and meta-analysis

Cited by 41 publications

References 33 publications

Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis

Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis

Cardiovascular biomarkers predict post‐discharge re‐hospitalization risk and mortality among Swedish heart failure patients

The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction

Contact Info

Product

Resources

About